Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
2008 1
2012 1
2014 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Is there 'progression through grade' in ductal invasive breast cancer?
Schymik B, Buerger H, Krämer A, Voss U, van der Groep P, Meinerz W, van Diest PJ, Korsching E. Schymik B, et al. Among authors: meinerz w. Breast Cancer Res Treat. 2012 Oct;135(3):693-703. doi: 10.1007/s10549-012-2195-1. Epub 2012 Aug 12. Breast Cancer Res Treat. 2012. PMID: 22886478
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.
Thomssen C, Vetter M, Kantelhardt EJ, Meisner C, Schmidt M, Martin PM, Clatot F, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jänicke F, Loibl S, Minckwitz GV, Harbeck N; NNBC 3-Europe Study Group. Thomssen C, et al. Among authors: meinerz w. Cancers (Basel). 2023 Mar 3;15(5):1580. doi: 10.3390/cancers15051580. Cancers (Basel). 2023. PMID: 36900372 Free PMC article.
Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.
Rhiem K, Bücker-Nott HJ, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, Latos K, Pelzer V, Seifert M, Schmidt A, Rezek D, Groh U, Meinerz W, Crommelinck D, Hahnen E, Wesselmann S, Schmutzler RK. Rhiem K, et al. Among authors: meinerz w. Breast J. 2019 May;25(3):455-460. doi: 10.1111/tbj.13257. Epub 2019 Apr 5. Breast J. 2019. PMID: 30953388
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B; GBG/AGO-B study groups; Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat… See abstract for full author list ➔ von Minckwitz G, et al. Among authors: meinerz w. Ann Oncol. 2014 Dec;25(12):2363-2372. doi: 10.1093/annonc/mdu455. Epub 2014 Sep 15. Ann Oncol. 2014. PMID: 25223482 Free article. Clinical Trial.